ProteomEdge Secures 7.8 million SEK in Funding to Accelerate Commercialization and Appoints New CEO

ProteomEdge is proud to announce the successful closure of a 7.8 million SEK funding round, led by Navigare Ventures, a subsidiary of Wallenberg Investments AB, with strong participation from existing shareholders.

This investment fuels our mission to deliver a cutting-edge analytical platform for absolute protein quantification using mass spectrometry. Our growing portfolio of proprietary products, targeting a large set of clinically relevant plasma biomarkers such as apolipoproteins, complement factors, and liver biomarkers, is already making impact in key research areas.

“This investment will enable us to expand our proprietary product line of internal standards for mass spectrometry platforms and bring them to market faster,” said Professor Mathias Uhlén, Co-founder and Chairman of the Board.

“Navigare Ventures is excited to lead this funding round to support the ProteomEdge team and their vision to bring precision into absolute proteome quantification for next-generation blood profiling,” said Elin Almstedt, Principal at Navigare Ventures.

We are also pleased to welcome Dr. Henrik Everberg as our new full-time Chief Executive Officer, starting August 2025. Dr. Everberg brings two decades of experience in the life science sector, with leadership roles at companies including PhaDia, Atlas Antibodies, and most recently as COO of Pixelgen Technologies. He succeeds Dr. Marianne Hansson, who has served as part-time CEO during our formative phase—our sincere thanks for her impactful leadership.

Stay tuned as ProteomEdge continues to push the boundaries of applied mass spectrometry-based proteomics and transform the future of blood-based precision medicine. 
Read more about ProteomEdge here: ProteomEdge – Unique concept for MS-based quantification